According to the FDA, the labeling alone should be adequate to communicate the risk of embryofetal toxicity. The Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation ...

The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The ...

The trial compares sparsentan, an oral pill developed by Travere Therapeutics, Inc., with the standard angiotensin receptor blocker irbesartan. Both drugs aim to slow kidney damage in focal segmental ...

Hydrogen sulfide can effectively reverse established hypoxia-induced PH and remodeling of pulmonary vascular structure in a rat model.

Tryvio is expected to be available in the second half of 2024. The Food and Drug Administration (FDA) has approved Tryvio ™ (aprocitentan) for the treatment of hypertension in combination with other ...

The study found no significant differences between the groups in terms of disease progression, morbidity or mortality, or all-cause death. Macitentan demonstrated superiority over other endothelin ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed ...

Expanded indication supported by mixed bag of trial data ...

Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.